Our Conversations Webinar Series is an opportunity to link national experts in colorectal cancer and other related fields to you, right in the comfort of your own home. The programs are designed to empower you to play a leading role in your healthcare management with your physician.
On August 26, 2015, we hosted the “Know Your Biomarker!” town hall, sponsored by Amgen, Inc., where we discussed personalized medicine and the role biomarkers may play in informing a metastatic colorectal cancer treatment plan.
Couldn’t make the webinar? No problem—we have the top 4 takeaways and the replay.
1. Personalized medicine is advancing—steps can be taken to identify patients that may be more likely to benefit, or may be at greater risk of adverse effects, from one treatment plan versus another.
2. For patients with metastatic colon cancer, biomarker testing is an important tool used to individualize your treatment plan. Biomarker testing provides knowledge about the genetic profile of your tumor to help you and your doctor choose the right patient care plan for you.
3. Several biomarkers identified as RAS (KRAS, NRAS) and BRAF may be important in metastatic colorectal cancer.
4. Knowing your biomarker status may help you and your doctor make important health care decisions, so please speak with your doctor about your biomarker status!
Be sure to download the slides.